418 related articles for article (PubMed ID: 32079420)
1. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
3. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
Vollack-Hesse N; Oleshko O; Werwitzke S; Solecka-Witulska B; Kannicht C; Tiede A
Blood; 2021 Feb; 137(8):1072-1081. PubMed ID: 32877516
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
5. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
[TBL] [Abstract][Full Text] [Related]
6. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
7. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
8. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.
Hu C; Lipshutz GS
Gene Ther; 2012 Dec; 19(12):1166-76. PubMed ID: 22241178
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
[TBL] [Abstract][Full Text] [Related]
10. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.
Mao J; Wang Y; Zhang W; Shen Y; Zhang G; Xi W; Wang Q; Ruan Z; Wang J; Xi X
Front Med; 2022 Aug; 16(4):584-595. PubMed ID: 35038106
[TBL] [Abstract][Full Text] [Related]
11. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
Samelson-Jones BJ; Arruda VR
Front Immunol; 2020; 11():618. PubMed ID: 32425925
[TBL] [Abstract][Full Text] [Related]
12. The F8(-/-) rat as a model of hemophilic arthropathy.
Sørensen KR; Roepstorff K; Wiinberg B; Hansen AK; Tranholm M; Nielsen LN; Kjelgaard-Hansen M
J Thromb Haemost; 2016 Jun; 14(6):1216-25. PubMed ID: 27060449
[TBL] [Abstract][Full Text] [Related]
13. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
14. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
Sarkar R; Xiao W; Kazazian HH
J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
[TBL] [Abstract][Full Text] [Related]
15. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
[TBL] [Abstract][Full Text] [Related]
17. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
19. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
